Summary & Overview
CPT 0619U: TruD MDS COPD DNA Methylation Test
CPT code 0619U designates a Proprietary Laboratory Analyses (PLA) test for TruD MDS COPD from TruDiagnostic™ Inc., a molecular diagnostic that assesses DNA methylation at over 18,000 sites from a whole blood sample and reports a positive or negative risk for chronic obstructive pulmonary disease (COPD). As a PLA code, 0619U is specific to a single manufacturer’s test and is intended to enable distinct tracking and reimbursement for that proprietary assay. Nationally, PLA codes like 0619U matter because they affect coverage pathways, claims processing, and comparative utilization reporting for novel diagnostics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical service setting, and the implications of PLA designation for billing and payer engagement. The publication summarizes available benchmarks and payer coverage context where available, highlights policy considerations tied to proprietary molecular diagnostics, and provides clinical context about the test’s role in COPD risk assessment. Data not available in the input is noted where relevant.
Billing Code Overview
CPT code 0619U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the TruD MDS COPD test from TruDiagnostic™ Inc. The test analyzes DNA methylation at more than 18,000 sites using a whole blood sample and uses a proprietary algorithm to report a positive or negative risk result for pulmonary chronic obstructive pulmonary disease (COPD).
Service Type: Laboratory — molecular diagnostic test (proprietary PLA)
Typical Site of Service: Clinical laboratory or reference laboratory using whole blood specimens
Clinical & Coding Specifications
Clinical Context
A typical adult patient with a history of tobacco use, chronic respiratory symptoms, or an abnormal spirometry result presents to a primary care clinician or pulmonologist for risk stratification for chronic obstructive pulmonary disease (COPD). The clinician orders the proprietary TruD MDS COPD test (0619U) performed by TruDiagnostic™ Inc., which requires a whole blood sample collected in a standard phlebotomy setting. The blood specimen is sent to the manufacturer’s laboratory; results are returned as a binary risk output (positive or negative) based on methylation profiling at >18,000 CpG sites and a proprietary algorithm.
Clinical workflow:
-
The clinician documents indications such as unexplained chronic cough, dyspnea, history of smoking, or abnormal pulmonary function testing and places the order for the TruD MDS COPD test (
0619U). -
A phlebotomy technician collects a whole blood specimen at an outpatient clinic, hospital outpatient lab, or ambulatory phlebotomy site; specimen handling and shipping follow the laboratory’s required protocol.
-
The specimen is transported to the manufacturer’s reference laboratory for DNA extraction, methylation analysis, and algorithmic interpretation.
-
The laboratory issues a report with a positive or negative COPD risk result to the ordering clinician. The clinician integrates the test result with clinical evaluation, smoking history, spirometry, imaging, and other diagnostic data to inform risk assessment and management planning.
Typical site of service: outpatient clinic, ambulatory phlebotomy center, hospital outpatient laboratory, or reference lab processing location.
Service type: Proprietary Laboratory Analysis (PLA) — high-complexity molecular diagnostic testing performed by a single laboratory/manufacturer.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use if separate billing for physician interpretation exists (rare for PLA tests). |
90 | Reference laboratory | Use when the test is performed by a reference laboratory distinct from the ordering facility. |
91 | Repeat clinical diagnostic laboratory test | Use when an identical test is repeated on the same day for verification of a prior result. |
59 | Distinct procedural service | Use when another unrelated service is performed on the same day that meets distinct procedural criteria. |
24 | Unrelated E/M service during postoperative period | Use if an unrelated evaluation is provided during a global period when billing an E/M separate from the test. |
25 | Significant, separately identifiable E/M service on the same day | Use when an unrelated and separately documented E/M is reported the same day as ordering or specimen collection. |
TC | Technical component | Use if separate billing for the technical component exists (uncommon for manufacturer PLA codes billed by reference lab). |
KX | Requirements specified in policy have been met | Use when payer-specific medical necessity criteria are documented and required for coverage. |
GA | Waiver of liability statement on file | Use when patient has signed an Advance Beneficiary Notice or similar waiver and payer requires the code. |
GQ | Remote/recorded transmission to an off-site location (telemedicine lab) | Use if test processing relies on remote transmission per payer-specific guidance. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
2084P0800X | Pulmonary Disease | Pulmonologists ordering COPD risk assessment and interpreting results. |
207Q00000X | Family Medicine | Primary care clinicians who evaluate chronic respiratory symptoms and order testing. |
208000000X | Internal Medicine | Internists managing COPD risk stratification and longitudinal care. |
363A00000X | Pathology & Laboratory Medicine | Laboratory directors and molecular pathology specialists overseeing test performance and reporting. |
1835S0200X | Clinical Laboratory | Clinical laboratory personnel involved in specimen handling and processing. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
J44.9 | Chronic obstructive pulmonary disease, unspecified | Common indication to assess COPD risk or stratify patients with suspected or known COPD. |
R06.02 | Shortness of breath | Symptom prompting evaluation including COPD risk assessment with molecular testing. |
R05 | Cough | Persistent cough is a typical presenting symptom leading to further evaluation for COPD. |
Z87.891 | Personal history of nicotine dependence | Smoking history increases pretest probability for COPD and is relevant to ordering the test. |
Z13.83 | Encounter for screening for respiratory tuberculosis (not COPD-specific) | May appear when screening respiratory risk; included for completeness when respiratory screening is performed alongside COPD evaluation. |
Z71.6 | Tobacco abuse counseling | Counseling encounters often co-occur with diagnostic evaluation for COPD risk. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0619U | TruD MDS COPD — DNA methylation analysis of >18,000 sites, whole blood; proprietary test providing positive/negative COPD risk | Primary PLA code for the proprietary methylation-based COPD risk assay performed by TruDiagnostic™ Inc.; billed when the manufacturer’s test is ordered and processed. |
36415 | Collection of venous blood by venipuncture | Performed at the ordering site to obtain the whole blood specimen required for 0619U. |
99000 | Handling and/or conveyance of specimen to reference laboratory (if payer allows) | May be used per payer or facility policy to report special specimen handling/shipping when separate reimbursement is permitted. |
G0499 | This code is not applicable to PLA testing and is listed here only if required by specific payers for molecular test reporting | Use only if a payer explicitly requires an alternate lab reporting code in conjunction with a PLA test (payer-specific situations). |
CPT not provided | Data not available in the input. | Additional local or payer-specific laboratory billing codes may apply for courier services, accessioning, or facility charges; use institutional billing guidance. |